CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart

被引：1
|
作者：
Skaar, Todd C. [1 ]
Desta, Zeruesenay [1 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期
关键词：
BREAST-CANCER; METABOLITE; BIOTRANSFORMATION; GENOTYPE;
D O I：
10.1002/cpt.1039
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.
引用
收藏
页码：755 / 757
页数：3
相关论文
共 50 条
  • [1] CYP2D6 and CYP3A influence tamoxifen and endoxifen
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) : 524 - 525
  • [2] Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy
    Schultink, Aurelia H. M. de Vries
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    BREAST, 2018, 42 : 38 - 40
  • [3] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J. Ruddy
    Stephen D. Desantis
    Rebecca S. Gelman
    Alan H. B. Wu
    Rinaa S. Punglia
    Erica L. Mayer
    Sara M. Tolaney
    Eric P. Winer
    Ann H. Partridge
    Harold J. Burstein
    Breast Cancer Research and Treatment, 2013, 141 : 421 - 427
  • [4] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Ruddy, Kathryn J.
    Desantis, Stephen D.
    Gelman, Rebecca S.
    Wu, Alan H. B.
    Punglia, Rinaa S.
    Mayer, Erica L.
    Tolaney, Sara M.
    Winer, Eric P.
    Partridge, Ann H.
    Burstein, Harold J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (03) : 421 - 427
  • [5] CYP2D6 Polymorphisms and the impact on tamoxifen therapy
    Beverage, Jacob N.
    Sissung, Tristan M.
    Sion, Amy M.
    Danesi, Romano
    Figg, William D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (09) : 2224 - 2231
  • [6] Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
    Lee, Clara Inkyung
    Low, Siew Kee
    Maldonado, Ricardo
    Fox, Peter
    Balakrishnar, Bavanthi
    Coulter, Sally
    de Bruijn, Peter
    Koolen, Stijn L. W.
    Gao, Bo
    Lynch, Jodi
    Zdenkowski, Nicholas
    Hui, Rina
    Liddle, Christopher
    Mathijssen, Ron H. J.
    Wilcken, Nicholas
    Wong, Mark
    Gurney, Howard
    BREAST, 2020, 54 : 229 - 234
  • [7] Correlation of endoxifen pharmacokinetics and CYP2D6 genotypes
    Tchu, S. M.
    Wang, P.
    Stone, J.
    Ziv, E.
    Lorizio, W.
    Wu, A.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A167 - A167
  • [8] Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections
    Lee, Clara Inkyung
    Gurney, Howard
    CANCER FORUM, 2016, 40 (03) : 4 - 10
  • [9] Endoxifen Levels Associated to CYP2D6 Phenotype
    Antunes, M., V
    Santos, T., V
    Andreolla, H.
    Rosa, D. D.
    Linden, R.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 710 - 710
  • [10] CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy
    Jansen, Laura E.
    Teft, Wendy A.
    Rose, Rhiannon V.
    Lizotte, Daniel J.
    Kim, Richard B.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 701 - 708
12345